by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder

Slides:

Advertisements

Similar presentations

by Johnny Mahlangu, Jerry S. Powell, Margaret V

Advertisements

Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival by Sandra L. Haberichter,

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase–dependent cleavage of calreticulin in AML patients by Sarah Mans, Yara Banz,

Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes.

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,

Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo by Ilze Bot, Jian Guo, Miranda Van Eck,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,

Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Arterioscler Thromb Vasc Biol

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci,

TCR-MHC-peptide(s): in vivo veritas

Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis.

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors by Glaivy Batsuli, Wei Deng, John.

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model by Eline Menu, Helena Jernberg-Wiklund,

by James O. Armitage, and Dan L. Longo

Next-generation leukemia immunotherapy

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C–mediated proteolysis by.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

The Molecular Basis for Cross-Reacting Material–Positive Hemophilia A Due to Missense Mutations Within the A2-Domain of Factor VIII by Kagehiro Amano,

Skovseth et al. Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood.

Mutagenic potential of temozolomide in bone marrow cells in vivo

Engineering regulatory T cells against factor VIII inhibitors

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation by Akio Mizutani, Kenji Okajima, Mitsuhiro.

by Rizwan Masood, Megan E

Cloning, expression, and functional characterization of the von Willebrand factor–cleaving protease (ADAMTS13)‏ by Barbara Plaimauer, Klaus Zimmermann,

Thrombin generation: biochemical possibilities and clinical reality

Hepatic low-density lipoprotein receptor–related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol by Sonia M. S.

How we choose factor VIII to treat hemophilia

Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome by Mihály Józsi, Stefanie Strobel, Hans-Martin.

Taking a leaf from the book of oral tolerance

VWF sequence variants: innocent until proven guilty

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Nuha Shiltagh, John Kirkpatrick, Lisa D. Cabrita, Tom A. J

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease. by Kenichi.

Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.

Blocking VWF platelet binding to treat TTP

Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10 by Alma Zernecke, Elisa A. Liehn,

C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,

Complex interactions between B cells and dendritic cells

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice by Rikke Stagaard, Carsten Dan Ley, Kasper Almholt,

by Kalpana Parvathaneni, and David W. Scott

Hemostasis in acute liver and kidney failure: nothing is as it seems

Stefano Toldo et al. BTS 2017;2:

The common VWF single nucleotide variants c. 2365A>G and c

by Juan Chen, Jocelyn A. Schroeder, Xiaofeng Luo, and Qizhen Shi

Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley Molecular Therapy

The von Willebrand Factor protein showing various functional domains that have been mapped to regions of the cDNA. The von Willebrand Factor protein showing.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Ca2+ infusion rates during all three protocol versions.

How I treat autoimmune hemolytic anemia

X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes by Hirokazu Kanegane,

Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action by Shiva Keshava, Jagan Sundaram,

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Interaction of platelet-decorated VWF strings with leukocytes and infected red blood cells in vitro. Interaction of platelet-decorated VWF strings with.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients by Elena.

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A by Barbara A. Konkle, Oleksandra Stasyshyn,

Gene editing in hemophilia: a “CRISPR” choice?

Cold agglutinin disease

Presentation transcript:

by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder In vivo inhibition of low density lipoprotein receptor–related protein improves survival of factor VIII in the absence of von Willebrand factor by Peter L. Turecek, Hans Peter Schwarz, and Bernd R. Binder Blood Volume 95(11):3637-3638 June 1, 2000 ©2000 by American Society of Hematology

Inhibition of LRP by RAP improves survival of infused human recombinant FVIII in vWf knockout mice.Animals were treated with 200 U/kg human rFVIII with and without preadministration of RAP (40 mg/kg). Inhibition of LRP by RAP improves survival of infused human recombinant FVIII in vWf knockout mice.Animals were treated with 200 U/kg human rFVIII with and without preadministration of RAP (40 mg/kg). FVIII antigen (FVIII:Ag) was measured by an ELISA specific for human FVIII. Group means are shown ± SD. Peter L. Turecek et al. Blood 2000;95:3637-3638 ©2000 by American Society of Hematology